Project Grant R13AI179131

Award Date 7/12/23
Completion Date 6/30/24
Dollars Obligated $7K
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Pennsylvania, USA
Similar Awards
This $510,306 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to advance the understanding of virus-host interactions for developing a cure against chronic hepatitis B virus (HBV) infections. The primary goal is to investigate the mechanisms by which interferon-alpha treatment can lead to a functional cure for HBV, as well as explore the impact of HBV...
This $847,428 federal Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 Allergy and Infectious Diseases Research) supports research to understand the mechanisms of hepatitis B virus (HBV) persistence and clearance in chronic hepatitis B patients, with a focus on evaluating intrahepatic cccDNA and integrated DNA. The primary awardee, Beth Israel Deaconess Medical Center, will conduct translational research to quantify cccDNA and integrated DNA levels,...
The Project Grant award R01AI179309 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) is funding a 5-year, $762,072 translational research project to discover a safe and effective long-acting antiviral therapy for hepatitis B (HBV). The research aims to leverage expertise and collaboration to transform existing short-acting oral antiviral drugs into a new long-acting injectable HBV therapy. Key goals...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under CFDA 93.855 Allergy and Infectious Diseases Research, provides $3,056,673 to The Johns Hopkins University to conduct research on the immunologic mechanisms associated with hepatitis B (HBV) vaccine responses in people living with HIV (PLWH). The key objectives are to: 1) Define the innate immune signatures of the HBV vaccine adjuvants CpG 1018 and alum, 2) Compare HBV-specific B and T cell...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $2,279,005 to The Johns Hopkins University to conduct research on hepatitis B virus (HBV) covalently closed circular DNA (cccDNA) transcriptional silencing, with a focus on comparing HBV mono-infection and HBV/HIV co-infection. The 5-year project aims to uncover the mechanisms underlying cccDNA transcriptional...
This Project Grant award of $162,000.00 was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the Pontificia Universidad Javeriana in Colombia. The project aims to evaluate the impact of reprogramming HBV-specific CD8+ T cells from individuals with chronic hepatitis B infection in order to enhance their antiviral potential. Specifically, the research will assess the effects of this...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $598,764 to The Trustees of Princeton University to conduct research aimed at disrupting the formation of HBV cccDNA to combat chronic HBV infection, particularly in the context of HIV co-infection. The key objectives are to: 1) determine whether genetic disruption of host factors involved in HBV cccDNA...
This federal Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847 - Diabetes, Digestive, and Kidney Diseases Extramural Research) provides $234,735 to The Regents of the University of California, San Francisco (UCSF) to conduct research on improving immune responses against hepatitis B virus (HBV) infection. The research aims to investigate the mechanisms behind age-related differences in the body's ability to clear HBV surface antigen, which...
This Project Grant award for $862,440.00 was made by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant supports the development and evaluation of a new humanized mouse model to study gene editing therapies targeting chronic hepatitis B virus (HBV) infection. The key objectives are to: 1) Evaluate the anti-HBV efficacy of HBV gene therapy in liver-humanized NSG-PIZ mice, including assessing...
The Department of the Army Medical Command awarded Hbvtech, L.L.C. a $4,728,039 Project Grant under the Military Medical Research and Development (CFDA 12.420) federal grant program. The grant supports Hbvtech's research and development of a novel hepatitis B virus (HBV) cure treatment regimen focused on the durable elimination of HBV covalently closed circular DNA in chronic HBV infections. The research objectives include creating AAV vector-based gene therapies and investigating methods to...

2023 INTERNATIONAL HBV MEETING - ABSTRACT/SUMMARY HEPATITIS B VIRUS (HBV) IS A MAJOR GLOBAL PUBLIC HEALTH THREAT WITH APPROXIMATELY 296 MILLION CHRONICALLY INFECTED PEOPLE WORLDWIDE AND OVER 800,000 DEATHS PER YEAR. CHRONIC HBV INFECTION IS A LEADING CAUSE FOR DEVELOPMENT OF LIVER CIRRHOSIS AND HEPATOCELLULAR CARCINOMA. DESPITE THE EFFECTIVENESS OF THE PROPHYLACTIC HBV VACCINE, IT HAS NO IMPACT ON ESTABLISHED CHRONIC INFECTIONS. CONSEQUENTLY, THERE IS A GREAT NEED TO DISCOVER NEW THERAPEUTIC STRATEGIES TO CURE CHRONIC HBV INFECTION AND SLOW OR STOP THE RESULTING DISEASE. THE ANNUAL INTERNATIONAL HBV MEETING IS THE ONLY FORUM THAT GATHERS THE INTERNATIONAL COMMUNITY OF RESEARCHERS WHO STUDY INFECTION, PERSISTENCE, PATHOGENESIS, AND DRUG DEVELOPMENT FOR HBV AND THE CLOSELY ASSOCIATED HEPATITIS DELTA VIRUS (HDV). THIS INTERNATIONAL HBV MEETING HAS BEEN HELD YEARLY SINCE 1985. IN 2023, THIS MEETING WILL BE HELD FOR THE FIRST TIME IN JAPAN, IN EAST ASIA WHERE CHRONIC HEPATITIS B IS HIGHLY ENDEMIC, WITH OVER 100 MILLION PEOPLE CHRONICALLY AFFECTED. SUCCESS OF THE INTERNATIONAL HBV MEETING RELIES ON THE CONTRIBUTIONS OF NOT ONLY THE ESTABLISHED INVESTIGATORS, BUT IMPORTANTLY, ALSO ON EARLY CAREER RESEARCHERS FROM DIVERSE BACKGROUNDS. TO FACILITATE THE PARTICIPATION OF YOUNG SCIENTISTS, WE REQUEST FUNDING TO SUPPORT TRAVEL EXPENSES FOR EARLY CAREER AND UNDER- REPRESENTED RESEARCHERS AT THE 2023 INTERNATIONAL HBV MEETING. THIS 2023 MEETING WILL PROVIDE THE OPPORTUNITY FOR SCIENTIFIC EXCHANGE AND DISSEMINATION OF THE LATEST RESEARCH INFORMATION TO DISCOVER NEW STRATEGIES FOR POTENTIALLY CURING HBV AND HDV. AN ESTIMATED 500-600 DELEGATES WILL ATTEND THE 2023 MEETING. THE MEETING WILL CONSIST OF 10 ORAL SCIENTIFIC SESSIONS, 2 POSTER SESSIONS, 3 PLENARY LECTURES FROM EXPERTS OUTSIDE OF THE HBV FIELD WHO WILL BRING DIFFERENT PERSPECTIVES, AND A LECTURE GIVEN BY THE RECIPIENT OF THE DISTINGUISHED AWARD IN HBV RESEARCH THAT IS AWARDED ANNUALLY BY THE MEETING. TOWARD THE GOAL OF CURING HBV AND HDV, THIS MEETING WILL BE SATELLITED BY HBV CURE SYMPOSIUM TO DISCUSS MECHANISMS UNDERLYING DURABILITY OF ANTI-HBV SIRNA THERAPY, AND BY AN HBV COMMUNITY FORUM WHERE SCIENTISTS FROM THE HBV COMMUNITY ENGAGE WITH THE GENERAL PUBLIC, MEDIA, STUDENTS AND THOSE AFFECTED BY HBV TO DISCUSS HBV/HDV AND THE RELATED DISEASES. AS IN THE PAST, GREAT EFFORT HAS BEEN MADE TO MINIMIZE THE COST OF THE MEETING. A MAJOR STRENGTH OF THE MEETING ORGANIZATION BEING CONTINUAL SUPPORT FROM THE HEPATITIS B FOUNDATION SINCE 2005. IN ORDER TO ENABLE AND FACILITATE PARTICIPATION OF EARLY CAREER RESEARCHERS AND UNDER-REPRESENTED MINORITY INVESTIGATORS TO MAXIMIZE THE SIGNIFICANCE OF THE MEETING, WE REQUEST SUPPORT FROM THE NATIONAL INSTITUTES OF HEALTH TO HELP DEFRAY THEIR TRAVEL COSTS. THIS FUNDING WILL BE USED TO ENSURE ATTENDANCE AND PRESENTATION BY EARLY CAREER RESEARCHERS, PARTICULARLY FROM LOW AND MIDDLE-INCOME COUNTRIES, AS WELL AS DISADVANTAGED AND UNDER-REPRESENTED MINORITY INVESTIGATORS.

Posted 7/12/23, 12:00 AM